Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis
Conclusions
Natalizumab was associated with superior outcomes over time for many patient-reported health and employment outcomes when compared with other DMTs in this large prospective cohort study. These findings may influence treatment selection in clinical practice and future treatment cost-effectiveness analyses.
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Chen, J., Diouf, I., Taylor, B. V., Kalincik, T., van der Mei, I. Tags: Multiple sclerosis Source Type: research
More News: Australia Health | Brain | Depression | Disability | Employment | Multiple Sclerosis | Neurology | Neurosurgery | Pain | Psychiatry | Study | Tysabri